{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:56:06Z","timestamp":1790636166723,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06820-4","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T09:34:41Z","timestamp":1790588081000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vibegron, mirabegron, and other add-on therapies for persistent overactive bladder symptoms in \u03b11-blocker-treated men with benign prostatic hyperplasia: a systematic review and Bayesian network meta-analysis"],"prefix":"10.1007","volume":"44","author":[{"given":"Shugo","family":"Yajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaku","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanobu","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"6820_CR1","unstructured":"Cornu JN, Elterman D, Hashim H et al (2026) EAU guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS). In: EAU Guidelines Edn. Presented at the EAU Annual Congress London 2026. EAU Guidelines Office, Arnhem, The Netherlands. (ISBN 978-94-92671-32-5)"},{"key":"6820_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-023-01327-1","volume":"23","author":"YT Su","year":"2023","unstructured":"Su YT, Chen HL, Teoh JYC et al (2023) Comparison of add-on medications for persistent storage symptoms after \u03b1-blocker treatment in BPH patients\u2014a network meta-analysis. BMC Urol 23:154. https:\/\/doi.org\/10.1186\/s12894-023-01327-1","journal-title":"BMC Urol"},{"key":"6820_CR3","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/nau.25399","volume":"43","author":"S Herschorn","year":"2024","unstructured":"Herschorn S, Tarcan T, Jiang YH et al (2024) Safety and efficacy of an \u03b11-blocker plus mirabegron compared with an \u03b11-blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: a systematic review and network meta-analysis. Neurourol Urodyn 43:604\u2013619. https:\/\/doi.org\/10.1002\/nau.25399","journal-title":"Neurourol Urodyn"},{"key":"6820_CR4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/JU.0000000000000807","volume":"204","author":"D Staskin","year":"2020","unstructured":"Staskin D, Frankel J, Varano S et al (2020) International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol 204:316\u2013324. https:\/\/doi.org\/10.1097\/JU.0000000000000807","journal-title":"J Urol"},{"key":"6820_CR5","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2022-4-2","author":"M Kennelly","year":"2022","unstructured":"Kennelly M, Wielage R, Shortino D, Thomas E, Mudd PN Jr (2022) Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis. Drugs Context. https:\/\/doi.org\/10.7573\/dic.2022-4-2","journal-title":"Drugs Context"},{"key":"6820_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/luts.12475","volume":"15","author":"W He","year":"2023","unstructured":"He W, Zhang Y, Huang G et al (2023) Efficacy and safety of vibegron compared with mirabegron for overactive bladder: a systematic review and network meta-analysis. Low Urin Tract Symp 15:80\u201388. https:\/\/doi.org\/10.1111\/luts.12475","journal-title":"Low Urin Tract Symp"},{"key":"6820_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"6820_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162:777\u2013784. https:\/\/doi.org\/10.7326\/M14-2385","journal-title":"Ann Intern Med"},{"key":"6820_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JPA (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64:163\u2013171. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.03.016","journal-title":"J Clin Epidemiol"},{"key":"6820_CR10","doi-asserted-by":"publisher","unstructured":"Phillippo DM (2026) multinma: Bayesian network meta-analysis of individual and aggregate data. R package version 0.9.1. https:\/\/doi.org\/10.5281\/zenodo.3904454","DOI":"10.5281\/zenodo.3904454"},{"key":"6820_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"6820_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou A, Higgins JPT, Papakonstantinou T et al (2020) CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med 17:e1003082. https:\/\/doi.org\/10.1371\/journal.pmed.1003082","journal-title":"PLoS Med"},{"key":"6820_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/luts.70053","volume":"18","author":"M Yoshida","year":"2026","unstructured":"Yoshida M, Nishino Y, Nagae H et al (2026) Efficacy and safety of vibegron add-on therapy for persistent overactive bladder symptoms in benign prostatic hyperplasia patients with \u03b11-blocker treatment: a multi-center prospective randomized controlled study (VATON study). Low Urin Tract Symp 18:e70053. https:\/\/doi.org\/10.1111\/luts.70053","journal-title":"Low Urin Tract Symp"},{"key":"6820_CR14","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/JU.0000000000003999","volume":"212","author":"D Staskin","year":"2024","unstructured":"Staskin D, Owens-Grillo J, Thomas E et al (2024) Efficacy and safety of vibegron for persistent symptoms of overactive bladder in men being pharmacologically treated for benign prostatic hyperplasia: results from the phase 3 randomized controlled COURAGE trial. J Urol 212:256\u2013266. https:\/\/doi.org\/10.1097\/JU.0000000000003999","journal-title":"J Urol"},{"key":"6820_CR15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/nau.70199","volume":"45","author":"ES Rovner","year":"2026","unstructured":"Rovner ES, Owens-Grillo J, Thomas E et al (2026) Bladder function and safety of vibegron in men with overactive bladder receiving treatment for benign prostatic hyperplasia: outcomes from the phase 3 randomized controlled COURAGE trial. Neurourol Urodyn 45:299\u2013304. https:\/\/doi.org\/10.1002\/nau.70199","journal-title":"Neurourol Urodyn"},{"key":"6820_CR16","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.euf.2019.10.019","volume":"6","author":"H Kakizaki","year":"2020","unstructured":"Kakizaki H, Lee KS, Yamamoto O et al (2020) Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: a randomized, placebo-controlled study (MATCH). Eur Urol Focus 6:729\u2013737. https:\/\/doi.org\/10.1016\/j.euf.2019.10.019","journal-title":"Eur Urol Focus"},{"key":"6820_CR17","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1097\/JU.0000000000000738","volume":"203","author":"SA Kaplan","year":"2020","unstructured":"Kaplan SA, Herschorn S, McVary KT et al (2020) Efficacy and safety of mirabegron versus placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying benign prostatic hyperplasia: a randomized, phase 4 study (PLUS). J Urol 203:1163\u20131171. https:\/\/doi.org\/10.1097\/JU.0000000000000738","journal-title":"J Urol"},{"key":"6820_CR18","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1002\/nau.23935","volume":"38","author":"Y Matsukawa","year":"2019","unstructured":"Matsukawa Y, Takai S, Majima T et al (2019) Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: a randomized, prospective trial using urodynamic studies. Neurourol Urodyn 38:941\u2013949. https:\/\/doi.org\/10.1002\/nau.23935","journal-title":"Neurourol Urodyn"},{"key":"6820_CR19","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00345-020-03425-3","volume":"39","author":"MG Soliman","year":"2021","unstructured":"Soliman MG, El-Abd SA, Tawfik AM, Radwan MH, El-Abd AS (2021) Efficacy and safety of mirabegron versus solifenacin as additional therapy for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO. World J Urol 39:2049\u20132054. https:\/\/doi.org\/10.1007\/s00345-020-03425-3","journal-title":"World J Urol"},{"key":"6820_CR20","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.urology.2011.02.055","volume":"78","author":"O Yamaguchi","year":"2011","unstructured":"Yamaguchi O, Kakizaki H, Homma Y et al (2011) Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms\u2014ASSIST, randomized controlled study. Urology 78:126\u2013133. https:\/\/doi.org\/10.1016\/j.urology.2011.02.055","journal-title":"Urology"},{"key":"6820_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1757-5672.2010.00081.x","volume":"3","author":"O Nishizawa","year":"2011","unstructured":"Nishizawa O, Yamaguchi O, Takeda M, Yokoyama O, TAABO Study Group (2011) Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. LUTS Lower Urin Tract Sympt 3:29\u201335. https:\/\/doi.org\/10.1111\/j.1757-5672.2010.00081.x","journal-title":"LUTS Lower Urin Tract Sympt"},{"key":"6820_CR22","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.urology.2013.05.008","volume":"82","author":"M Takeda","year":"2013","unstructured":"Takeda M, Nishizawa O, Gotoh M et al (2013) Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite \u03b1-blocker treatment in patients with BPH: the ADDITION study. Urology 82:887\u2013893. https:\/\/doi.org\/10.1016\/j.urology.2013.05.008","journal-title":"Urology"},{"key":"6820_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.juro.2016.08.116","volume":"197","author":"JC Kim","year":"2017","unstructured":"Kim JC, Cho KJ, Lee JG et al (2017) Efficacy and safety of desmopressin add-on therapy for men with persistent nocturia on \u03b1-blocker monotherapy for lower urinary tract symptoms: a randomized, double-blind, placebo controlled study. J Urol 197:459\u2013464. https:\/\/doi.org\/10.1016\/j.juro.2016.08.116","journal-title":"J Urol"},{"key":"6820_CR24","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00345-014-1399-x","volume":"33","author":"O Yokoyama","year":"2015","unstructured":"Yokoyama O, Tsujimura A, Akino H et al (2015) Add-on anticholinergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving \u03b11-blocker treatment: a multi-centre, prospective, randomised study. World J Urol 33:659\u2013667. https:\/\/doi.org\/10.1007\/s00345-014-1399-x","journal-title":"World J Urol"},{"key":"6820_CR25","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.juro.2014.09.091","volume":"193","author":"K Ichihara","year":"2015","unstructured":"Ichihara K, Masumori N, Fukuta F, Tsukamoto T, Iwasawa A, Tanaka Y (2015) A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol 193:921\u2013926. https:\/\/doi.org\/10.1016\/j.juro.2014.09.091","journal-title":"J Urol"},{"key":"6820_CR26","doi-asserted-by":"publisher","first-page":"419","DOI":"10.4111\/icu.2020.61.4.419","volume":"61","author":"SY Kwon","year":"2020","unstructured":"Kwon SY, Park DJ, Seo YJ, Lee KS (2020) Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: a prospective study. Investig Clin Urol 61:419\u2013424. https:\/\/doi.org\/10.4111\/icu.2020.61.4.419","journal-title":"Investig Clin Urol"},{"key":"6820_CR27","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.eururo.2008.11.026","volume":"56","author":"C Chapple","year":"2009","unstructured":"Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z (2009) Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with \u03b1-blockers. Eur Urol 56:534\u2013541. https:\/\/doi.org\/10.1016\/j.eururo.2008.11.026","journal-title":"Eur Urol"},{"key":"6820_CR28","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1016\/j.juro.2009.08.023","volume":"182","author":"SA Kaplan","year":"2009","unstructured":"Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W (2009) Safety and tolerability of solifenacin add-on therapy to \u03b1-blocker treated men with residual urgency and frequency. J Urol 182:2825\u20132830. https:\/\/doi.org\/10.1016\/j.juro.2009.08.023","journal-title":"J Urol"},{"key":"6820_CR29","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1111\/j.1464-410X.2011.10624.x","volume":"109","author":"SA Kaplan","year":"2012","unstructured":"Kaplan SA, Roehrborn CG, Gong J, Sun F, Guan Z (2012) Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving \u03b1-blocker treatment for lower urinary tract symptoms. BJU Int 109:1831\u20131840. https:\/\/doi.org\/10.1111\/j.1464-410X.2011.10624.x","journal-title":"BJU Int"},{"key":"6820_CR30","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/00029330-200703010-00004","volume":"120","author":"Y Yang","year":"2007","unstructured":"Yang Y, Zhao XF, Li HZ et al (2007) Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Chin Med J (Engl) 120:370\u2013374. https:\/\/doi.org\/10.1097\/00029330-200703010-00004","journal-title":"Chin Med J (Engl)"},{"key":"6820_CR31","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1159\/000345050","volume":"90","author":"C Konstantinidis","year":"2013","unstructured":"Konstantinidis C, Samarinas M, Andreadakis S, Xanthis S, Skriapas K (2013) Lower urinary tract symptoms associated with benign prostatic hyperplasia: combined treatment with fesoterodine fumarate extended-release and tamsulosin\u2014a prospective study. Urol Int 90:156\u2013160. https:\/\/doi.org\/10.1159\/000345050","journal-title":"Urol Int"},{"key":"6820_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2026.115321","author":"R Mohamed-Ahmed","year":"2026","unstructured":"Mohamed-Ahmed R, Rantell A, Robinson D (2026) Comparing the safety and efficacy of vibegron, mirabegron and tolterodine in patients with overactive bladder: a systematic review and network meta-analysis. Eur J Obstet Gynecol Reprod Biol. https:\/\/doi.org\/10.1016\/j.ejogrb.2026.115321","journal-title":"Eur J Obstet Gynecol Reprod Biol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06820-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06820-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06820-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:03:26Z","timestamp":1790633006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06820-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6820"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06820-4","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"10 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable; this systematic review and network meta-analysis used previously published data and involved no new research with human participants or animals.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"712"}}